Generic Hemangeol Availability
Last updated on Aug 7, 2024.
Hemangeol is a brand name of propranolol, approved by the FDA in the following formulation(s):
HEMANGEOL (propranolol hydrochloride - solution;oral)
-
Manufacturer: PIERRE FABRE
Approval date: March 14, 2014
Strength(s): 4.28MG/ML [RLD]
Has a generic version of Hemangeol been approved?
No. There is currently no therapeutically equivalent version of Hemangeol available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hemangeol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent 8,338,489
Issued: December 25, 2012
Inventor(s): Léauté-Labrèze Christine & Dumas De La Roque Éric & Taieb Alain & Thambo Jean-Benoît
Assignee(s): Université Victor Segalen—Bordeaux 2The present disclosure relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present disclosure provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Patent expiration dates:
- October 16, 2028✓
- October 16, 2028
-
Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent 8,987,262
Issued: March 24, 2015
Inventor(s): Leaute-Labreze Christine & Dumas De La Roque Eric & Taieb Alain & Thambo Jean-BenoitThe present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
Patent expiration dates:
- October 16, 2028✓
- October 16, 2028
More about Hemangeol (propranolol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: group II antiarrhythmics
- Breastfeeding
- En español
Patient resources
Other brands
Inderal, Inderal XL, InnoPran XL
Professional resources
Other brands
Inderal, Inderal LA, Inderal XL, InnoPran XL
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.